I-Corps: Non-invasive ventilation treatment for COPD patients

I-Corps：慢性阻塞性肺病患者的无创通气治疗

• 批准号: 1822281
• 负责人: Jacob Brenner
• 金额: $ 5万
• 依托单位: University of Pennsylvania
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-01 至 2018-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1822281&HistoricalAwards=false
• 关键词: Corps; Non; invasive; ventilation; treatment

The broader impact/commercial potential of this I-Corps is a novel noninvasive ventilation modality for treatment of mild and severe chronic obstructive pulmonary disease (COPD) patients. Two million Americans have such severe COPD that, even on maximal medical therapy, they are unable to walk up a single flight of stairs due to severe shortness of breath. As the disease progresses, patients become bound to their house, their chair, and finally their bed. This technology provides a non-intrusive pulmonary support to patients in a form of a lightweight, mobile, and noninvasive ventilator, which can help support these patients during physical activity and help them live a full life again, free of suffocation. Long term impacts of this technology include: (1) increased quality of life and treatment effectiveness for severe COPD patients; (2) development of novel pulmonary rehabilitation therapies; (3) expansion of noninvasive ventilation technology in the field of pulmonary care to supplement and enhance current ventilation techniques.This I-Corps project is a mobile, non-invasive ventilation technology targeted at COPD patients. The device works by supplementing patient's breathing with pressure changes on their chest and abdomen. With each breath in, the device generates a vacuum that helps lift the chest and abdomen, helping the patient breathe in. With each breath out, the device increases pressure over the chest and helps the patient breath out faster. By assisting the work of breathing, patients no longer feel short of breath and can once again engage in normal daily activities. The device promotes a healthy breathing cycle, which prevents hyperinflation of the airways and degeneration of alveoli in the lungs. Noninvasive ventilation and pulmonary rehabilitation have both been shown to have significant, positive effects on the quality of life and medical outcomes of COPD patients. The technology aims to improve patient's well-being.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps具有更广泛的影响/商业潜力，是一种用于治疗轻度和重度慢性阻塞性肺疾病（COPD）患者的新型无创通气模式。 200万美国人患有严重的COPD，即使接受最大限度的药物治疗，他们也无法因严重的呼吸急促而走上一段楼梯。随着病情的发展，病人会被束缚在他们的房子、椅子上，最后是床上。该技术以轻便、移动的和无创呼吸机的形式为患者提供非侵入性肺部支持，可以在体力活动期间帮助支持这些患者，并帮助他们再次过上完整的生活，免于窒息。该技术的长期影响包括：（1）提高重度COPD患者的生活质量和治疗效果;（2）开发新型肺康复疗法;（3）扩展肺部护理领域的无创通气技术，以补充和增强当前的通气技术。该I-Corps项目是针对COPD患者的移动的无创通气技术。该装置的工作原理是通过患者胸部和腹部的压力变化来补充患者的呼吸。每次吸气时，该设备都会产生真空，帮助提升胸部和腹部，帮助患者吸气。 每次呼气时，该设备都会增加胸部的压力，帮助患者更快地呼气。 通过辅助呼吸工作，患者不再感到呼吸急促，可以再次进行正常的日常活动。该设备促进健康的呼吸循环，防止气道过度充气和肺泡退化。无创通气和肺康复均被证明对COPD患者的生活质量和医疗结局具有显著的积极影响。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。